Relationship of sense of coherence to stressful events, coping strategies, health status, and quality of life in women with breast cancer

2011 ◽  
Vol 22 (1) ◽  
pp. 20-27 ◽  
Author(s):  
Elisabeth Kenne Sarenmalm ◽  
Maria Browall ◽  
L.-O. Persson ◽  
J. Fall-Dickson ◽  
Fanny Gaston-Johansson
Nursing Open ◽  
2021 ◽  
Author(s):  
Hadi Zamanian ◽  
Mohammadali Amini‐Tehrani ◽  
Aliyeh Mahdavi Adeli ◽  
Mona Daryaafzoon ◽  
Mahnaz Arsalani ◽  
...  

2019 ◽  
Vol 3 (1) ◽  
Author(s):  
A. Barnadas ◽  
◽  
M. Muñoz ◽  
M. Margelí ◽  
J. I. Chacón ◽  
...  

Abstract Background Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM. Methods Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL. Results Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0–1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity. Conclusions BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients. Trial registration NCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).


1992 ◽  
Vol 45 (5) ◽  
pp. 473-485 ◽  
Author(s):  
Patricia A. Ganz ◽  
J.Jack Lee ◽  
Myung-Shin Sim ◽  
Margaret L. Polinsky ◽  
C.Anne Coscarelli Schag

2004 ◽  
Vol 19 (2) ◽  
pp. 139-155 ◽  
Author(s):  
Trace Kershaw ◽  
Laurel Northouse ◽  
Charuwan Kritpracha ◽  
Ann Schafenacker ◽  
Darlene Mood

2020 ◽  
Vol 26 (6) ◽  
pp. 1421-1428
Author(s):  
Ebrahim Salehifar ◽  
Ghasem Janbabaei ◽  
Abbas Alipour ◽  
Nasim Tabrizi ◽  
Razieh Avan

Purpose Taxane-induced peripheral neuropathy (TIPN) is a common and bothersome toxicity. This study aimed to determine the incidence and severity of TIPN in patients with breast cancer and to investigate the relationship between TIPN and quality of life. Methods A total of 82 breast cancer patients with TIPN symptoms were included in this study. The criteria of National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.03) and the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30, version 3.0) were used to evaluate grading of sensory neuropathy and quality of life, respectively. Analysis of the data was done by IBM SPSS statistics version 23. Results A total of 346 patients received taxane-based chemotherapy and 82 patients (23.7%) experience TIPN. The mean (SD) global health status/quality of life, physical functioning, role functioning, and pain subscales were 60.63 (5.26), 80.64 (9.05), 81.77 (10.41), and 43.88 (11.27), respectively. There were significant negative correlations between global health status/quality of life, physical functioning, and role functioning subscales with the grade of neuropathy (r = −0.33, −0.80, and −0.61, respectively) and positive correlation between pain subscale and the grade of neuropathy (r = 0.70). Conclusion This study shows a clear association between TIPN and worsened quality of life. These findings emphasize on detecting and management of TIPN in an effort to improve the quality of life of breast cancer patients.


2020 ◽  
Vol 60 (9) ◽  
pp. 1063-1069
Author(s):  
Lilian Velasco ◽  
Lorena Gutiérrez Hermoso ◽  
Natasha Alcocer Castillejos ◽  
Paulina Quiroz Friedman ◽  
Cecilia Peñacoba ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document